Mazdutide
vs Survodutide.
Compare mazdutide and survodutide by GLP-1/glucagon dual agonism, China approval, Phase 3 obesity results, liver programs, FDA status, and cross-trial limits.
What is the difference?
Mazdutide and survodutide are separate once-weekly GLP-1 and glucagon receptor dual agonists, and no head-to-head trial has compared them. Mazdutide has Chinese approvals for chronic weight management and type 2 diabetes, while survodutide remains investigational and has reported Phase 3 obesity results plus a dedicated liver-disease program. Neither drug is FDA approved. Their shared receptor class does not make the molecules interchangeable, and results from GLORY and SYNCHRONIZE cannot establish which program is more effective, safer, or better for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Mazdutide
Approved in China for chronic weight management and type 2 diabetes; not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 37 matched NCT records
- Sponsor
- Innovent Biologics; licensed from Eli Lilly for China
Survodutide
Investigational - not approved for marketing
- Route
- Once-weekly subcutaneous injection
- Registry
- 31 matched NCT records
- Sponsor
- Boehringer Ingelheim + Zealand Pharma
Mazdutide vs Survodutide: how direct is the evidence?
No participant in the cited sources was randomized between Mazdutide and Survodutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Mazdutide
GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; Phase 3 and indication-expansion studies continue
- Status
- Approved in China for chronic weight management and type 2 diabetes; not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialSurvodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 10
- Results posted
- 1
- Recruiting site observations
- 73
matched NCT records
- Recruiting
- 3
- Results posted
- 3
- Recruiting site observations
- 774
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Mazdutide
GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; Phase 3 and indication-expansion studies continue
- Status
- Approved in China for chronic weight management and type 2 diabetes; not FDA approved
- Featured trial anchors
- NCT05607680 · NCT06164873 · NCT06184568 · NCT05606913
Survodutide
Glucagon + GLP-1 receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program active and reporting
- Status
- Investigational - not approved for marketing
- Featured trial anchors
- NCT06066515 · NCT06066528 · NCT06077864 · NCT06309992
Compare the field, then read the limit.
This identity and evidence comparison matters because both drugs use the same two headline receptor targets. Quick summaries can therefore imply that they are substitutes or rank the largest trial percentages without checking molecule design, receptor balance, population, duration, estimand, adverse-event discontinuation, liver-focused development, or approval geography. The country-specific status difference is as important as the numerical result.
| Field | Mazdutide | Survodutide | How to interpret it |
|---|---|---|---|
| Receptor class | GLP-1 and glucagon receptor dual agonist | Glucagon and GLP-1 receptor dual agonist | The same headline targets do not mean identical receptor balance, molecule design, dosing, or clinical effect. |
| Regulatory status | Approved in China for weight management and type 2 diabetes; not FDA approved | Phase 3 active and reporting; no marketing approval recorded and not FDA approved | Mazdutide's approval is jurisdiction-specific, while a completed Phase 3 result is not an approval. |
| Obesity evidence anchor | 14.01% at 48 weeks for 6 mg in GLORY-1 | 13.0% at 76 weeks for 6 mg under the treatment-regimen estimand in SYNCHRONIZE-1 | The matching dose number does not make the molecules, protocols, estimands, or populations comparable. |
| Additional development focus | Type 2 diabetes, obesity complications, MASH, and heart-failure studies | Dedicated MASH, MASLD, liver-fat, fibrosis, and obesity programs | Disease-specific programs answer different clinical questions and should not be converted into a general winner claim. |
| Studied route | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection | A shared schedule under study does not establish equivalent formulations, approved doses, tolerability, or local access. |
Why the headline numbers do not name a winner.
GLORY-1 reported 14.01% mean weight reduction for 6 mg mazdutide at 48 weeks, and GLORY-2 reported 16.65% for 9 mg at 60 weeks in separate Chinese Phase 3 populations. SYNCHRONIZE-1 reported 13.0% for 6 mg survodutide at 76 weeks under the treatment-regimen estimand and up to 16.6% under an efficacy estimand. The trials did not randomize mazdutide against survodutide, and their analysis methods, countries, durations, escalation plans, and placebo responses differ.
Keep the comparison honest.
- 01
Do not treat two GLP-1/glucagon dual agonists as synonyms, substitutes, or evidence for one another.
- 02
Keep China approval, FDA status, and every other country's product and seller records separate.
- 03
Compare trial estimates only with their dose, duration, population, comparator, estimand, and adverse-event context attached.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →